Latest Healthcare News

Page 2 of 195
Ryman Healthcare’s FY26 retirement living sales hit 1,410 ORAs, aligning with guidance despite a Q4 dip in new sales. The company reports robust aged care occupancy and expects free cash flow near NZD 180 million.
Ada Torres
Ada Torres
15 Apr 2026
Telix Pharmaceuticals has initiated a US$550 million convertible bonds offering to refinance existing 2029 bonds and support general corporate purposes, securing low-cost, non-dilutive financing with a conversion premium above current share price.
Ada Torres
Ada Torres
14 Apr 2026
Rhythm Biosciences has clarified inconsistencies in its disclosures around termination events in its underwriting agreement for RHYO options, following an ASX query. The company acknowledged an incomplete initial summary and administrative oversights but confirmed the agreement remains in full effect.
Ada Torres
Ada Torres
14 Apr 2026
Holista Colltech’s shares remain suspended on the ASX following a trading halt linked to ongoing legal issues with ProImmune Company LLC, with no resolution in sight.
Ada Torres
Ada Torres
14 Apr 2026
Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.
Ada Torres
Ada Torres
14 Apr 2026
PainChek has secured a landmark agreement with Sabra Health Care REIT to deploy its AI-powered pain assessment across up to 20,000 beds in North America, marking a pivotal step in its US expansion.
Ada Torres
Ada Torres
14 Apr 2026
Clarity Pharmaceuticals has secured a major manufacturing deal with Nucleus RadioPharma to produce its next-generation prostate cancer imaging agent, 64Cu-SAR-bisPSMA, ramping up supply ahead of anticipated US market entry.
Ada Torres
Ada Torres
14 Apr 2026
Audeara Ltd has posted its second straight quarter of positive operating cash flow, driven by a record Australian wholesale order and expanding technology licensing deals. The company’s cash balance rose to $1.05 million as it advances global market expansions.
Ada Torres
Ada Torres
14 Apr 2026
Vectus Biosystems has completed the sale of its VB4-P5 renal fibrosis compound to Canadian biotech XORTX, receiving a near 10% equity stake and warrants. This move aligns with Vectus’ strategy to develop drug candidates to a stage attractive to partners while focusing on its lead compound VB0004.
Ada Torres
Ada Torres
14 Apr 2026
Green Cross Health (NZX: GXH) has acknowledged discussions with third parties about a possible sale of its Medical division but emphasised that no transaction is guaranteed. The company remains committed to updating shareholders as the situation develops.
Ada Torres
Ada Torres
14 Apr 2026
Pro Medicus has secured a 5-year, A$37 million contract renewal with Northwestern Medicine, featuring higher minimum usage commitments and increased fees per transaction, reflecting growth in exam volumes.
Ada Torres
Ada Torres
13 Apr 2026
EMVision Medical Devices has ramped up recruitment in its pivotal FDA trial across eight hospitals and is nearing results from multiple pre-hospital studies, all while bolstering its cash position with a $3.8 million R&D tax refund and $6.6 million in grant funding.
Ada Torres
Ada Torres
13 Apr 2026